Katarzyna Rafa-Zablocka

Dr. Katarzyna Rafa-Zablocka

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2014 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
ABAgnieszka Basta-Kaim
Agnieszka Basta-Kaim
ESEwa Szczesny
Ewa Szczesny
KGKatarzyna Głombik
Katarzyna Głombik
Katarzyna StachowiczKatarzyna Stachowicz
Katarzyna Stachowicz
JSJoanna Slusarczyk
Joanna Slusarczyk
WLWładysław Lasoń
Władysław Lasoń

1 November 2013 in Pharmacological Reports
Verified
Journal Article
Closed access
Irena NalepaIrena Nalepa
Irena Nalepa
GKGrzegorz Kreiner
Grzegorz Kreiner
Adam BielawskiAdam Bielawski
Adam Bielawski
KRKatarzyna Rafa-Zablocka
Katarzyna Rafa-Zablocka
ARAdam Roman
Adam Roman

27 March 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
GKGrzegorz Kreiner
Grzegorz Kreiner
KRKatarzyna Rafa-Zablocka
Katarzyna Rafa-Zablocka
JBJustyna Barut
Justyna Barut
PCPiotr Chmielarz
Piotr Chmielarz
MKMarta Kot
Marta Kot
Irena NalepaIrena Nalepa
Irena Nalepa
Parkinson’s disease (PD) is the second most common neurodegenerative disorder and is characterized by motor deficits such as tremor, rigidity and bradykinesia. These symptoms are directly caused by the loss of dopaminergic neurons. However, a wealth of clinical evidence indicates that the dopaminergic system is not the only system affected in PD. Postmortem studies of brains from PD patients have revealed the degeneration of noradrenergic neurons in the locus coeruleus (LC) to the same or even greater extent than that observed in the dopaminergic neurons of substantia nigra (SN) and ventral tegmental area (VTA). Moreover, studies performed on rodent models suggest that enhancement of noradrenergic transmission may attenuate the PD-like phenotype induced by MPTP administration, a neurotoxin-based PD model. The aim of this study was to investigate whether chronic treatment with either of two compounds targeting the noradrenergic system (reboxetine or atipamezole) possess the ability to reduce the progression of a PD-like phenotype in a novel mouse model of progressive dopaminergic neurodegeneration induced by the genetic inhibition of rRNA synthesis in dopaminergic neurons, mimicking a PD-like phenotype. The results showed that reboxetine improved the parkinsonian phenotype associated with delayed progression of SN/VTA dopaminergic neurodegeneration and higher dopamine content in the striatum. Moreover, the alpha1-adrenergic agonist phenylephrine enhanced survival of TH+ neurons in primary cell cultures, supporting the putative neuroprotective effects of noradrenergic stimulation. Our results provide new insights regarding the possible influence of the noradrenergic system on dopaminergic neuron survival and strongly support the hypothesis regarding the neuroprotective role of noradrenaline.

20 September 2018 in Frontiers in Neuroscience
Verified
Journal Article
Open access
PDF file
KRKatarzyna Rafa-Zablocka
Katarzyna Rafa-Zablocka
GKGrzegorz Kreiner
Grzegorz Kreiner
MBMonika Bagińska
Monika Bagińska
Irena NalepaIrena Nalepa
Irena Nalepa
Neurotrophic factors are regarded as crucial regulatory components in neuronal plasticity and are postulated to play an important role in depression pathology. The abundant expression of brain-derived neurotrophic factor (BDNF) in various brain structures seems to be of particular interest in this context, as downregulation of BDNF is postulated to be correlated with depression and its upregulation is often observed after chronic treatment with common antidepressants. It is well-known that BDNF expression is regulated by cyclic AMP response element-binding protein (CREB). In our previous study using mice lacking CREB in serotonergic neurons (Creb1TPH2CreERT2 mice), we showed that selective CREB ablation in these particular neuronal populations is crucial for drug-resistant phenotypes in the tail suspension test observed after fluoxetine administration in Creb1TPH2CreERT2 mice. The aim of this study was to investigate the molecular changes in the expression of neurotrophins in Creb1TPH2CreERT2 mice after chronic fluoxetine treatment, restricted to the brain structures implicated in depression pathology with profound serotonergic innervation including the prefrontal cortex (PFC) and hippocampus. Here, we show for the first time that BDNF upregulation observed after fluoxetine in the hippocampus or PFC might be dependent on the transcription factor CREB residing, not within these particular structures targeted by serotonergic projections, but exclusively in serotonergic neurons. This observation may shed new light on the neurotrophic hypothesis of depression, where the effects of BDNF observed after antidepressants in the hippocampus and other brain structures were rather thought to be regulated by CREB residing within the same brain structures. Overall, these results provide further evidence for the pivotal role of CREB in serotonergic neurons in maintaining mechanisms of antidepressant drug action by regulation of BDNF levels.

18 October 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
KRKatarzyna Rafa-Zablocka
Katarzyna Rafa-Zablocka
GKGrzegorz Kreiner
Grzegorz Kreiner
MBMonika Bagińska
Monika Bagińska
JKJustyna Kusmierczyk
Justyna Kusmierczyk
RPRosanna Parlato
Rosanna Parlato
Irena NalepaIrena Nalepa
Irena Nalepa
Evidence exists that chronic antidepressant therapy enhances CREB levels and activity. Nevertheless, the data are not conclusive, as previous analysis of transgenic mouse models has suggested that CREB inactivation in fact contributes to antidepressant-like behavior. The aim of this study was to evaluate the role of CREB in this context by exploiting novel transgenic mouse models, characterized by selective ablation of CREB restricted to noradrenergic (Creb1DBHCre/Crem−/−) or serotonergic (Creb1TPH2CreERT2/Crem−/−) neurons in a CREM-deficient background to avoid possible compensatory effects of CREM. Selective and functional ablation of CREB affected antidepressant-like behavior in a tail suspension test (TST) after antidepressant treatment. Contrary to single Creb1DBHCre mutants, Creb1DBHCre/Crem−/− mice did not respond to acute desipramine administration (20 mg/kg) on the TST. On the other hand, single Creb1TPH2CreERT2 mutants displayed reduced responses to fluoxetine (10 mg/kg) on the TST, while the effects in Creb1TPH2CreERT2/Crem−/− mice differed by gender. Our results provide further evidence for the important role of CREM as a compensatory factor. Additionally, the results indicate that new models based on the functional ablation of CREB in select neuronal populations may represent a valuable tool for investigating the role of CREB in the mechanism of antidepressant therapy.

11 June 2021 in Pharmacological Reports
Verified
Journal Article
Open access
PDF file
KRKatarzyna Rafa-Zablocka
Katarzyna Rafa-Zablocka
Agnieszka Zelek-MolikAgnieszka Zelek-Molik
Agnieszka Zelek-Molik
BTBeata Tepper
Beata Tepper
PCPiotr Chmielarz
Piotr Chmielarz
GKGrzegorz Kreiner
Grzegorz Kreiner
Irena NalepaIrena Nalepa
Irena Nalepa
Background: Evidence indicates that Gα12, Gα13, and its downstream effectors, RhoA and Rac1, regulate neuronal morphology affected by stress. This study was aimed at investigating whether repeated stress influences the expression of proteins related to the Gα12/13 intracellular signaling pathway in selected brain regions sensitive to the effects of stress. Furthermore, the therapeutic impact of β(1)adrenergic receptors (β1AR) blockade was assessed. Methods: Restraint stress (RS) model in mice (2 h/14 days) was used to assess prolonged stress effects on the mRNA expression of Gα12, Gα13, RhoA, Rac1 in the prefrontal cortex (PFC), hippocampus (HIP) and amygdala (AMY). In a separate study, applying RS model in rats (3–4 h/1 day or 14 days), we evaluated stress effects on the expression of Gα12, Gα11, Gαq, RhoA, RhoB, RhoC, Rac1/2/3 in the HIP. Betaxolol (BET), a selective β1AR antagonist, was introduced (5 mg/kg/p.o./8–14 days) in the rat RS model to assess the role of β1AR in stress effects. RT-qPCR and Western Blot were used for mRNA and protein assessments, respectively. Results: Chronic RS decreased mRNA expression of Gα12 and increased mRNA for Rac1 in the PFC of mice. In the mice AMY, decreased mRNA expression of Gα12, Gα13 and RhoA was observed. Fourteen days of RS exposure increased RhoA protein level in the rats’ HIP in the manner dependent on β1AR activity. Conclusions: Together, these results suggest that repeated RS affects the expression of genes and proteins known to be engaged in neural plasticity, providing potential targets for further studies aimed at unraveling the molecular mechanisms of stress-related neuropsychiatric diseases.